Gabriel EM and Lattime EC. Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res, 13(3):785-8, 2007. PMID: 17289867
DiPaola RS and Lattime EC. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy. J Urol, 178(5):1840-1, 2007. PMID: 17868741
Nikitczuk KP, Lattime EC, Schloss RS and Yarmush ML. Analysis of dendritic cell stimulation utilizing a multi-faceted nanopolymer delivery system and the immune modulator 1-methyl tryptophan. Nano Life, 1(3-4):239-50, 2010. PMID: 24772192, PMCID: PMC3998209
Moloughney JG, Monken CE, Tao H, Zhang H, Thomas JD, Lattime EC and Jin S. Vaccinia virus leads to ATG12-ATG3 conjugation and deficiency in autophagosome formation. Autophagy, 7(12):1434-47, 2011. PMID: 22024753, PMCID: PMC3327614
Nikitczuk KP, Schloss RS, Yarmush ML and Lattime EC. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival. J Cancer Ther, 4(1):280-90, 2013. PMID: 23741626, PMCID: PMC3670804
Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, third edition, edited by EC Lattime and SL Gerson. San Diego: Academic Press, 537 pp, 2013.
de Vries CR, Poplin E, Weiss RE, August DA, Gabriel E, DiPaola RS and Lattime EC. Poxvirus-based strategies for combined vaccine and tumor microenvironment manipulation In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, third edition, edited by EC Lattime and SL Gerson. San Diego: Academic Press, 241-257, 2013.
de Vries CR, Monken CE and Lattime EC. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther, 22(3):154-62, 2015. PMID: 25633483, PMCID: PMC4397129
DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH and Wilding G. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol, 68(3):365-71, 2015. PMID: 25533418, PMCID: PMC4472612
de Vries CR, Kaufman HL and Lattime EC. Oncolytic viruses: Focusing on the tumor microenvironment. Cancer Gene Ther, 22(4):169-71, 2015. PMID: 25721204
Cui R, Yue W, Lattime EC, Stein MN, Xu Q and Tan XL. Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget, 7(31):50735-54, 2016. PMID: 27191744, PMCID: PMC5226617
Sharp, DW and Lattime EC. Recombinant poxvirus and the tumor microenvironment: oncolysis, immune regulation and immunization. Biomedicines, 4(3):19, 2016. PMID: 28191451, PMCID: PMC5298125
Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, Monken CE, Shafikhani SH, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL and Zloza A. Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Rep, 17(4):957-65, 2016. PMID: 27760326, PMCID: PMC5589518
Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G and Ganesan S. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol, 1:1-13, 2017. PMID: 29951597; PMCID: PMC6016848
Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD and White E. Autophagy maintains tumour growth through circulating arginine. Nature, 563(7732): 569-73, 2018. PMID: 30429607; PMCID: PMC6287937
Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA and Lattime EC. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Ther, 2019. PMID: 31222182; PMCID: PMC6923616
